1013 Assessing HIV treatment related worries and stigma: Psychometric properties of a novel, brief patient-reported outcome measure Irina Kolobova 1 , Tamra Keeney 2 , Christina Donatti 3 , Amara Orji 2 , Lauren Henning 2 , Dominy Browning 3 , Mark Kosinski 2 1 ViiV Healthcare, Durham, North Carolina, USA, 2 IQVIA Quality Metric, Inc., Providence, Rhode Island, USA, 3 ViiV Healthcare, London, UK Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :1013 Aims Many people with HIV (PWH) experience heightened emotional burden and challenges related to daily oral medication regimens, which impact well-being and treatment adherence
at 2025C (typical room temperature), degradation accelerates to 3040% loss in the same timeframe
Muscle loss is a meaningful risk during rapid weight loss, particularly at higher doses
Because so many brand products share this single molecule, anchoring the discussion on semaglutide itself rather than on any one brand keeps the comparisons honest and helps you evaluate a given preparation on how it is made and verified rather than on the familiarity of a name attached to it
: ,
The points below describe potential research-observed benefits , not approved medical or therapeutic claims
